Skip to main content
Top
Published in: Endocrine 2/2018

01-05-2018 | Original Article

Longitudinal AddiQoL scores may identify higher risk for adrenal crises in Addison’s disease

Authors: Gesine Meyer, Maike Koch, Eva Herrmann, Jörg Bojunga, Klaus Badenhoop

Published in: Endocrine | Issue 2/2018

Login to get access

Abstract

Purpose

Several studies have shown a reduced quality of life (QoL) in patients with Addison’s disease (AD), but investigations of QoL over a long-term course are lacking. Adrenal crises (AC) are life-threatening complications in AD. The purpose of this prospective study was to test whether the repeated use of QoL-questionnaires can detect prodromal periods of an AC.

Methods

110 patients with AD were asked to complete the disease specific-QoL questionnaire AddiQoL and a short questionnaire about adverse events once monthly over a period of ten months. AC was defined if at least two of the following symptoms were reported: (a) hypotension, (b) nausea or vomiting, (c) severe fatigue, (d) documented hyponatremia, hyperkalemia, or hypoglycemia, and subsequent parenteral glucocorticoid administration was carried out.

Results

Prevalence of AC was 10.9/100 patient years. AddiQoL scores in patients with AC showed a trend (p = 0,08) to a wider fluctuation over time. Subjective precrises not meeting the criteria for AC were reported by 31 patients who had significantly lower AddiQoL scores (p = 0,018).

Conclusions

These are the first data showing the course of QoL during a period of ten months in patients with AD. Incidence of AC exceeds previous data. Our data show, that subjective precrises in AD associate with lower QoL. AC, as well as precrises affect intraindividual AddiQol-scores over time with a trend to a stronger fluctuation. Longitudinal AddiQol scores and self-reporting of precrises via patient diaries are additional clinical tools to identify higher risk for critical events.
Literature
1.
go back to reference S. Hahner, M. Loeffler, B. Bleicken et al., Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur. J. Endocrinol. 162, 597–602 (2010)CrossRefPubMed S. Hahner, M. Loeffler, B. Bleicken et al., Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur. J. Endocrinol. 162, 597–602 (2010)CrossRefPubMed
2.
go back to reference L.C. Smans, E.S. Van der Valk, A.R. Hermus, P.M. Zelissen, Incidence of adrenal crisis in patients with adrenal insufficiency. Clin. Endocrinol. 84, 17–22 (2016)CrossRef L.C. Smans, E.S. Van der Valk, A.R. Hermus, P.M. Zelissen, Incidence of adrenal crisis in patients with adrenal insufficiency. Clin. Endocrinol. 84, 17–22 (2016)CrossRef
3.
go back to reference S. Hahner, C. Spinnler, M. Fassnacht, et al., High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J. Clin. Endocrinol. Metab. 100, 407–416 (2015)CrossRefPubMed S. Hahner, C. Spinnler, M. Fassnacht, et al., High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J. Clin. Endocrinol. Metab. 100, 407–416 (2015)CrossRefPubMed
4.
go back to reference G. Meyer, K. Badenhoop, R. Linder, Addison’s disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German Health insurance data 2010-2013. Clin. Endocrinol. 85, 347–353 (2016)CrossRef G. Meyer, K. Badenhoop, R. Linder, Addison’s disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German Health insurance data 2010-2013. Clin. Endocrinol. 85, 347–353 (2016)CrossRef
5.
go back to reference K. White, W. Arlt, Adrenal crisis in treated Addison’s disease: a predictable but under-managed event. Eur. J. Endocrinol. 162, 115–120 (2010)CrossRefPubMed K. White, W. Arlt, Adrenal crisis in treated Addison’s disease: a predictable but under-managed event. Eur. J. Endocrinol. 162, 115–120 (2010)CrossRefPubMed
6.
go back to reference T.H. Puar, N.M. Stikkelbroeck, L.C. Smans et al., Adrenal crisis: still a deadly event in the 21st century. Am. J. Med. 129(339), e1–e9 (2016) T.H. Puar, N.M. Stikkelbroeck, L.C. Smans et al., Adrenal crisis: still a deadly event in the 21st century. Am. J. Med. 129(339), e1–e9 (2016)
7.
go back to reference B. Bleicken, S. Hahner, M. Loeffler et al., Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur. J. Endocrinol. 159, 811–817 (2008)CrossRefPubMed B. Bleicken, S. Hahner, M. Loeffler et al., Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur. J. Endocrinol. 159, 811–817 (2008)CrossRefPubMed
8.
go back to reference S. Hahner, M. Loeffler, M. Fassnacht et al., Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912–3922 (2007)CrossRefPubMed S. Hahner, M. Loeffler, M. Fassnacht et al., Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912–3922 (2007)CrossRefPubMed
9.
go back to reference K. Lovas, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease. Clin. Endocrinol. (Oxf.). 56, 581–588 (2002)CrossRefPubMed K. Lovas, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease. Clin. Endocrinol. (Oxf.). 56, 581–588 (2002)CrossRefPubMed
10.
go back to reference J. Tiemensma, C.D. Andela, A.A. Kaptein et al., Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. Eur. J. Endocrinol. 171, 171–182 (2014)CrossRefPubMed J. Tiemensma, C.D. Andela, A.A. Kaptein et al., Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. Eur. J. Endocrinol. 171, 171–182 (2014)CrossRefPubMed
11.
go back to reference K. Lovas, S. Curran, M. Oksnes et al., Development of a disease-specific quality of life questionnaire in Addison’s disease. J. Clin. Endocrinol. Metab. 95, 545–551 (2010)CrossRefPubMed K. Lovas, S. Curran, M. Oksnes et al., Development of a disease-specific quality of life questionnaire in Addison’s disease. J. Clin. Endocrinol. Metab. 95, 545–551 (2010)CrossRefPubMed
12.
go back to reference M. Oksnes, S. Bensing, A.L. Hulting et al., Quality of life in European patients with Addison’s disease: validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568–576 (2012)CrossRefPubMed M. Oksnes, S. Bensing, A.L. Hulting et al., Quality of life in European patients with Addison’s disease: validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568–576 (2012)CrossRefPubMed
13.
go back to reference L. Gagliardi, M.A. Nenke, T.R. Thynne et al., Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 99, 4149–4157 (2014)CrossRefPubMed L. Gagliardi, M.A. Nenke, T.R. Thynne et al., Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 99, 4149–4157 (2014)CrossRefPubMed
14.
go back to reference J. Langenheim, M. Ventz, A. Hinz, M. Quinkler, Modified-release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency. Horm. Metab. Res. 45, 96–101 (2013)PubMed J. Langenheim, M. Ventz, A. Hinz, M. Quinkler, Modified-release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency. Horm. Metab. Res. 45, 96–101 (2013)PubMed
15.
go back to reference M. Quinkler, R. Miodini Nilsen, K. Zopf et al., Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 (2015)CrossRefPubMed M. Quinkler, R. Miodini Nilsen, K. Zopf et al., Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 (2015)CrossRefPubMed
16.
go back to reference G. Meyer, A. Hackemann, M. Penna-Martinez, K. Badenhoop, What affects the quality of life in autoimmune Addison’s disease? Horm. Metab. Res. 45, 92–95 (2013)CrossRefPubMed G. Meyer, A. Hackemann, M. Penna-Martinez, K. Badenhoop, What affects the quality of life in autoimmune Addison’s disease? Horm. Metab. Res. 45, 92–95 (2013)CrossRefPubMed
17.
go back to reference A.H. Heald, A. Walther, J.R.E. Davis et al., No difference in mood and quality of life in dhea-s deficient adults with addison’s disease vs. type 2 diabetes patients with normal DHEA-S levels: implications for management of these conditions. Front Psychol. 8, 764 (2017)CrossRefPubMedPubMedCentral A.H. Heald, A. Walther, J.R.E. Davis et al., No difference in mood and quality of life in dhea-s deficient adults with addison’s disease vs. type 2 diabetes patients with normal DHEA-S levels: implications for management of these conditions. Front Psychol. 8, 764 (2017)CrossRefPubMedPubMedCentral
18.
go back to reference M. Henry, P.S. Wolf, I.L. Ross, K.G. Thomas, Poor quality of life, depressed mood, and memory impairment may be mediated by sleep disruption in patients with Addison’s disease. Physiol. Behav. 151, 379–385 (2015)CrossRefPubMedPubMedCentral M. Henry, P.S. Wolf, I.L. Ross, K.G. Thomas, Poor quality of life, depressed mood, and memory impairment may be mediated by sleep disruption in patients with Addison’s disease. Physiol. Behav. 151, 379–385 (2015)CrossRefPubMedPubMedCentral
19.
go back to reference S.R. Bornstein, B. Allolio, W. Arlt et al., Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016)CrossRefPubMed S.R. Bornstein, B. Allolio, W. Arlt et al., Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016)CrossRefPubMed
20.
go back to reference E.S. Husebye, B. Allolio, W. Arlt et al., Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 (2014)CrossRefPubMed E.S. Husebye, B. Allolio, W. Arlt et al., Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 (2014)CrossRefPubMed
21.
go back to reference H.J. Repping-Wuts, N.M. Stikkelbroeck, A. Noordzij et al., A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. Eur. J. Endocrinol. 169, 17–22 (2013)CrossRefPubMed H.J. Repping-Wuts, N.M. Stikkelbroeck, A. Noordzij et al., A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. Eur. J. Endocrinol. 169, 17–22 (2013)CrossRefPubMed
22.
go back to reference P. Tyrer, S. Cooper, M. Crawford et al., Prevalence of health anxiety problems in medical clinics. J. Psychosom. Res. 71, 392–394 (2011)CrossRefPubMed P. Tyrer, S. Cooper, M. Crawford et al., Prevalence of health anxiety problems in medical clinics. J. Psychosom. Res. 71, 392–394 (2011)CrossRefPubMed
23.
go back to reference P.M. Stewart, B.M. Biller, C. Marelli et al., Exploring inpatient hospitalizations and morbidity in patients with adrenal insufficiency. J. Clin. Endocrinol. Metab. 101, 4843–4850 (2016)CrossRefPubMed P.M. Stewart, B.M. Biller, C. Marelli et al., Exploring inpatient hospitalizations and morbidity in patients with adrenal insufficiency. J. Clin. Endocrinol. Metab. 101, 4843–4850 (2016)CrossRefPubMed
24.
go back to reference J. Daniels, E. Sheils, A complex interplay: cognitive behavioural therapy for severe health anxiety in Addison’s disease to reduce emergency department admissions. Behav. Cogn. Psychother. 45, 419–426 (2017)CrossRefPubMed J. Daniels, E. Sheils, A complex interplay: cognitive behavioural therapy for severe health anxiety in Addison’s disease to reduce emergency department admissions. Behav. Cogn. Psychother. 45, 419–426 (2017)CrossRefPubMed
25.
go back to reference J. Daniels, J.M. Turner-Cobb, Adjuvant psychological therapy in long-term endocrine conditions. Clin. Endocrinol. 86, 772–777 (2017)CrossRef J. Daniels, J.M. Turner-Cobb, Adjuvant psychological therapy in long-term endocrine conditions. Clin. Endocrinol. 86, 772–777 (2017)CrossRef
26.
go back to reference S. Hahner, N. Hemmelmann, M. Quinkler et al., Timelines in the management of adrenal crisis-targets, limits and reality. Clin. Endocrinol. (Oxf.). 82, 497–502 (2015)CrossRefPubMed S. Hahner, N. Hemmelmann, M. Quinkler et al., Timelines in the management of adrenal crisis-targets, limits and reality. Clin. Endocrinol. (Oxf.). 82, 497–502 (2015)CrossRefPubMed
27.
go back to reference C. Leblicq, D. Rottembourg, J. Deladoey et al., Are guidelines for glucocorticoid coverage in adrenal insufficiency currently followed? J. Pediatr. 158, 492–498 (2011). e1CrossRefPubMed C. Leblicq, D. Rottembourg, J. Deladoey et al., Are guidelines for glucocorticoid coverage in adrenal insufficiency currently followed? J. Pediatr. 158, 492–498 (2011). e1CrossRefPubMed
Metadata
Title
Longitudinal AddiQoL scores may identify higher risk for adrenal crises in Addison’s disease
Authors
Gesine Meyer
Maike Koch
Eva Herrmann
Jörg Bojunga
Klaus Badenhoop
Publication date
01-05-2018
Publisher
Springer US
Published in
Endocrine / Issue 2/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1513-0

Other articles of this Issue 2/2018

Endocrine 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.